Molecular Formula | C21H25ClFN3O3 |
Molar Mass | 421.89 |
Density | 1.272±0.06 g/cm3(Predicted) |
Melting Point | 151-153°C |
Boling Point | 549.2±50.0 °C(Predicted) |
Flash Point | 286°C |
Solubility | DMSO: 50 mg/mL mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, try to use it now) Cell experiment: dissolve with DMSO first, then dilute with culture medium, |
Vapor Presure | 4.11E-12mmHg at 25°C |
Appearance | White to off-white crystalline solid |
Color | White to Off-White |
pKa | 13.52±0.46(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
Refractive Index | 1.584 |
MDL | MFCD00867430 |
melting point 151-153 °c.
2-aminomethyl-4-(4-fluorobenzyl) morpholine in dichloromethane, 4-amino -5-chloro-2-ethoxybenzoic acid and 1-ethyl -3-( 3-= methylaminopropyl) carbodiimide hydrochloride were added and stirred at 2596 for 4H. The reaction solution was washed with water, an aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium chloride in that order, and dried. After filtration and concentration under reduced pressure, the obtained material was recrystallized from ethanol to obtain mosapride. Mosapride was dissolved in ethanol and a 35% solution of hydrogen chloride in ethanol was added. The precipitate was collected by filtration and recrystallized from ethanol to obtain mosapride hydrochloride. Mosapride was dissolved in a hot 10% aqueous solution of citric acid and then slowly cooled. The precipitate was collected by filtration to obtain mosapride citrate dihydrate.
developed by Dainippon Corporation, Japan, which was first launched in Japan in 1998. 5 serotonin (5-HT4) receptor agonist, stimulate the release of acetylcholine, enhance the stomach and duodenum movement, is a new safe and effective digestive tract power drug. Mainly for functional dyspepsia accompanied by heartburn, heating, Nausea, Vomit, early satiety, upper abdominal distension and other gastrointestinal symptoms; Can also be used for gastroesophageal reflux disease, diabetic gastroparesis and partial gastrectomy in patients with gastric dysfunction.
mosapride citrate, male, female, mouse, rat LD50(mg/kg): >3000,> 3000,> 3000, 1905 orally;>1000,914,>10 00,>10 00 intraperitoneal injection I all> 1000 subcutaneous injection; Male, female dogs oral (mglkg): Both> 400.